SCHEMBL9934160

SCHEMBL9934160

Cc1cc(OCCCO[Si](C)(C)C(C)(C)C)cc(C)c1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
MAPT P10636 5/20 0.36
LMNA P02545 3/20 0.36
DUT P33316 2/20 0.36
STAT3 P40763 1/20 0.35
NOD2 Q9HC29 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 2/20 0.35
PDIA6 Q15084 1/20 0.33
TP53 P04637 3/20 0.32
MAPK1 P28482 3/20 0.32
GAA P10253 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KDM4E B2RXH2 2/20 0.30
MCL1 Q07820 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL578484 0.78 KDM4E (0.53) ALDH1A1DUTTSHRMAPK1KDM4E
SCHEMBL16624375 0.77 MAPT (0.43) MAPTDUTTSHRPDIA6KDM4E
SCHEMBL21883773 0.76 POLB (0.36) ALDH1A1LMNADUTHPGDTSHR
SCHEMBL4737246 0.76 MAPT (0.44) ALDH1A1MAPTLMNADUTSTAT3
SCHEMBL1250704 0.76 CA12 (0.40) ALDH1A1MAPTLMNASTAT3NOD2
SCHEMBL16624370 0.76 PDIA6 (0.38) MAPTDUTPDIA6TP53GAA
SCHEMBL16624376 0.76 PDIA6 (0.38) MAPTDUTTSHRPDIA6TP53
SCHEMBL27083521 0.76 KDM4E (0.36) ALDH1A1DUTKDM4E
SCHEMBL3079743 0.75 DUT (0.36) DUT
SCHEMBL16515501 0.74 ALDH1A1 (0.44) ALDH1A1MAPTLMNASTAT3NOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-09-24 US disclosed
US-20150225392-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9072758-B2 Cyclic amide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-07-07 US disclosed
US-9040525-B2 Cyclic amide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 US disclosed
EP-2703393-A1 CYCLIC AMIDE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2014-03-05 EP disclosed
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-02-27 US disclosed
US-20130203739-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-08-08 US disclosed
US-8476287-B2 3-hydroxy-5-arylisothiazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-07-02 US disclosed
EP-2518060-A1 NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2012-10-31 EP disclosed
US-20120157459-A1 NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 ALDH1A1 3399/4885MAPT 4733/4885LMNA 3943/4885
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 ALDH1A1 3072/4885MAPT 4734/4885LMNA 4092/4885
US-20150225392-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR2C2 ALDH1A1 3218/4885MAPT 4646/4885LMNA 3503/4885
US-20120157459-A1 NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE GPR119, GPR27, NR0B1 ALDH1A1 2875/4885MAPT 4385/4885LMNA 4218/4885
US-20130203739-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR2C2 ALDH1A1 3127/4885MAPT 4683/4885LMNA 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.